Literature DB >> 9101000

Extent and variation of omeprazole prescribing in an elderly population of Ontario.

J E McBride1, J L Pater, J L Dorland, Y M Lam.   

Abstract

OBJECTIVE: To determine the extent of omeprazole prescribing in the senior population of Ontario over a 1-year period; the variation in omeprazole prescribing for this population according to age group, gender, and geographic region: and the extent of inappropriate prescribing of omeprazole for this population.
DESIGN: Retrospective drug utilization review of prescription drug insurance claims. DATA SOURCE: The Ontario Drug Benefit (ODB) program claims database. OUTCOME MEASURES: The following outcomes were measured: the proportion of seniors in Ontario who received a prescription for omeprazole from April 1, 1992 to March 31, 1993: effects of age group, gender, and geographic region of residence on omeprazole prescribing; and the extent of inappropriate omeprazole prescribing according to the ODB criteria for use. Prescribing of omeprazole was defined as inappropriate if a first-line antiulcer drug (i.e., histamine2-receptor antagonist) was not prescribed within 1-6 months of the first prescription claim for omeprazole.
RESULTS: A total of 29,936 seniors in Ontario received omeprazole from April 1, 1992 to March 31, 1993 (2.53 recipients per 100 eligible population). The age-gender group most frequently prescribed omeprazole was women 65-74 years, followed by women and men 75 years or older, and then men 65-74 years. Omeprazole prescribing varied widely among the 48 provincial counties (range of 1.66 recipients per 100 eligible population to 4.52 recipients per 100 population, p < 0.001). There was no evidence of a clustering effect in omeprazole prescribing at the county level. Prescribing of omeprazole was considered to be inappropriate for 80.5% of recipients.
CONCLUSIONS: This study demonstrated the ineffectiveness of the ODB limited-use program in controlling omeprazole prescribing. Further study should be done to examine determinants of variation in prescribing by geographic region.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9101000     DOI: 10.1177/106002809703100404

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  5 in total

1.  Impact of reference-based pricing for histamine-2 receptor antagonists and restricted access for proton pump inhibitors in British Columbia.

Authors:  John K Marshall; Paul V Grootendorst; Bernie J O'Brien; Lisa R Dolovich; Anne M Holbrook; Adrian R Levy
Journal:  CMAJ       Date:  2002-06-25       Impact factor: 8.262

2.  Inappropriate drug use and risk of transition to nursing homes among community-dwelling older adults.

Authors:  Ilene H Zuckerman; Patricia Langenberg; Mona Baumgarten; Denise Orwig; Patricia J Byrns; Linda Simoni-Wastila; Jay Magaziner
Journal:  Med Care       Date:  2006-08       Impact factor: 2.983

3.  Pharmaceutical care and its relationship to prescribing behaviour of general practitioners.

Authors:  Paul E M Muijrers; Richard P T M Grol; Jildou Sijbrandij; Rob Janknegt; J André Knottnerus
Journal:  Pharm World Sci       Date:  2006-11-17

4.  Proton pump inhibitors. Compliance with a mandated step-up program.

Authors:  M M Mamdani; K Tu; L Jaakkimainen; A Bica; J Hux
Journal:  Can Fam Physician       Date:  2001-03       Impact factor: 3.275

5.  Compliance with restrictions on the subsidized use of proton pump inhibitors in Australia.

Authors:  P McManus; J Marley; D J Birkett; J Lindner
Journal:  Br J Clin Pharmacol       Date:  1998-10       Impact factor: 4.335

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.